Lemtrada Advisory Committee’s Flexibility May Not Make FDA Bend
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel agrees with agency that Genzyme’s pivotal trials for MS drug don’t meet FDA approval standards, then casts conflicting votes supporting drug.